Business Wire

Life Science: Cerba HealthCare to Acquire Canadian Contract Research Laboratory CIRION BioPharma Research to Expand Bioanalytical Capabilities and Shorten Time-to-Deploy Complex Clinical Trials

7.9.2023 10:00:00 EEST | Business Wire | Press release

Share

Cerba HealthCare, a leading global player in medical diagnosis, today announced it has acquired CIRION BIOPHARMA RESEARCH INC (CIRION), a Canadian-controlled private company highly recognized for its integrated bioanalytical and global central laboratory services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230907759314/en/

CIRION, a leading contract research organization has been operating global clinical trials over 30 years. Besides its bioanalytical capabilities highly specialized in Biosimilars/Biologics development including PKPD and Immunogenicity testing, it offers central lab full solutions with fast start-up capabilities for managing international multi-center clinical studies and supports specimen management for complex development projects. The company has a workforce of over 80 employees comprised of PhD holders, medical specialists and a network of renowned university researchers.

Cerba HealthCare appreciates CIRION’s reputation for its deep expertise with Large Molecules development and, high-quality services being fully GLP compliant, with an impressive client base including some of the world’s top 10 global pharmaceutical companies. Being CAP (College of American Pathologists) and CLIA (Clinical Laboratory Improvement Amendments) accredited assures that their lab is scientifically endorsed to regulatory standards in the North American market.

CIRION offers a full range of services, from the development of specialized assays to laboratory testing required for clinical studies, allowing the company to meet the complex needs of their reputable clients. Furthermore, the company provides R&D services from preclinical drug discovery to phase IV clinical stage drug development.

Within Cerba HealthCare’s comprehensive Group offering, and ranking under the Cerba Research brand, clinical laboratory and diagnostic solutions for clinical and IVD trials have grown considerably over the past years, demonstrating a strong track record in patient recruitment and clinical trial sample testing, as well as in white-glove logistics solutions for immuno-oncology, anti-infectives, cell & gene therapies and metabolic disorders. Over the years, Cerba Research has evolved to become the precision medicine partner to CROs, the biotechnology and pharmaceutical industry, and non-profit organizations with growing needs for global complex clinical research programs.

CIRION will rank under Cerba HealthCare’s business unit Cerba Research adding to its global network of cutting-edge laboratories in the Americas, Europe, Africa and Asia-Pacific. CIRION’s full-service offering will fit perfectly into Cerba Research’s multispecialty services portfolio and complement it. By combining deep expertise and agility of a specialist laboratory with the capacity, breadth and global reach of a central lab, Cerba Research is expanding its one-stop-shop offering for its clients.

Cerba Research CEO Mario Papillon said: “I see CIRION as a true strategic step in improving our offering both geographically and scientifically. It deepens our North American presence while featuring sound expertise in PKPD assay development and testing, which is instrumental knowledge for our customers as it relates drug concentration to drug effect. Their extensive knowledge and unrivalled reputation will naturally make CIRION the Cerba Research center of excellence in bioanalytics across the globe, helping us accelerate fulfill our clients’ needs in the development of personalized medicine. We are proud to welcome CIRION’s renowned high-quality scientists and very much looking forward to onboarding the team.

Dr. Sylvain Desrochers and Dr. Lise Dallaire, founders of CIRION added: We are very proud of what CIRION has accomplished over the past 30 years, and yet, it was time to find a new foundation to bring our scientific contribution to the next level. It is an honor to join the Cerba HealthCare galaxy though their world class clinical research provider: with Cerba Research, we found the perfect breeding ground where our combined expertise and capabilities will help our teams meet the ever-changing scientific, logistical and analytical challenges of clinical studies. This is truly galvanizing stage for our people to see their purpose pursued at a greater scale and we will remain closely associated to the business operations of this new entity. The CIRION scientists and experts are very excited to join Cerba Research in their continuous quest to provide the best possible solutions to serve and improve the clinical trials of our life science customers.”

About Cerba HealthCare

Cerba HealthCare, a leading global player in medical diagnosis, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine. Every day, on 5 continents, the Group’s 15 000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.

Cerba HealthCare, enlightening health.

Additional information is available at www.cerbahealthcare.com

About Cerba Research

We offer world-class clinical research that helps life science companies to successfully develop the predictive and precision medicines of the future.​

We combine the deep expertise and agility of the specialist laboratory with the capacity, breadth and global reach of a central lab. Our unique approach to patient data offers our customers the opportunity to have one partner for all their test services, with regular access and consistent support across all clinical trial phases.​

Our customer centric approach means flexible solutions to unique challenges, providing reassurance and efficacy, whilst offering agility at scale. Our customers today are our partners tomorrow.

For more information visit www.cerbaresearch.com

About CIRION

CIRION is a leading contract research laboratory providing global central laboratory services for clinical studies and bioanalytical services highly specialized in Biologics/Biosimilars. It offers a comprehensive selection of PKPD/Immunogenicity methods’ development and validation, project management and clinical testing services (GLP and non GLP).

Based in the Montreal metropolitan area, a strategic hub for the management of multinational clinical trials, CIRION is well positioned to respond efficiently to international project requirements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contacts:

Cerba HealthCare
Emmanuelle Saby
+33 6 09 10 76 10
emmanuelle.saby@cerbahealthcare.com

CIRION BioPharma Research Inc.
Dr Sylvain Desrochers
+1 (450) 682-2231
desrocherss@cirion.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Completed the Divestiture of Soy Crush, Concentrates and Lecithin Businesses2.3.2026 23:15:00 EET | Press release

IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its soy crush, concentrates and lecithin businesses to Bunge. This transaction does not include IFF’s soy isolates business. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260302231096/en/

Verimatrix ReAccess Earns Gold 2026 Merit Award for Telecom & Wireless2.3.2026 18:50:00 EET | Press release

Regulatory News: Verimatrix (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced that its Verimatrix ReAccess solution was honored with a gold 2026 Merit Award for Telecom & Wireless. The industry accolade recognizes the company’s next-generation content security solution that modernizes legacy Conditional Access Systems (CAS) across DVB, IPTV and OTT networks without requiring costly hardware replacements or field service interventions. Judged by industry executives, media professionals and technology consultants, the Merit Awards evaluate submissions from across the telecommunications landscape. Verimatrix ReAccess enables secure, over-the-air (OTA) software updates to deployed set-top boxes (STBs), delivering operator cost savings, reduced operational complexity, and ongoing protection against piracy. It also empowers operators to continuously strengthen content security, eliminating the need for costly hardware replacements. U

Textron Aviation Launches Donation Campaign to Support 2026 Special Olympics Airlift; Continues Nationwide Call for Volunteer Doves2.3.2026 18:00:00 EET | Press release

Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced the launch of a donation campaign benefitting Special Olympics in support of the 2026 Special Olympics Airlift, a nationwide effort that brings athletes and coaches to the Special Olympics USA Games through the generosity of volunteer pilots, aircraft owners and operators known as Doves. Financial contributions go directly to the Special Olympics, a 501(c)(3) charitable organization. New for the 2026 event, the donation campaign serves a vital role in ensuring each delegation has what it needs for a smooth and welcoming travel experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302196418/en/ Textron Aviation launches donation campaign to support 2026 Special Olympics Airlift; continues nationwide call for volunteer Doves (Photo credit: Textron Aviation). “This campaign reflects the spirit of unity and generosity that defines the Special Olym

Forrester Announces The Agenda For Its 2026 CX Events To Help Address The Challenges AI Can’t Handle Alone2.3.2026 16:30:00 EET | Press release

Forrester (Nasdaq: FORR) today announced the agenda for its global customer experience (CX) event series: CX Summit EMEA, being held in Amsterdam, June 8–10, 2026; CX Forum East, being held in New York City, June 16–17, 2026; and CX Forum West, being held in San Francisco, June 29–30, 2026. Today, CX, marketing, and digital business leaders are under mounting pressure to leverage AI to architect smarter end-to-end customer journeys, automate service, operationalize AI agents, and deliver true personalization at scale — all while consumer trust is at an all-time low. While AI is promising to raise the bar for speed and efficiency, beneath every customer experience is a foundation that AI alone can’t build. To forge trust, organizations need to embed human creativity, context, customer identity, and quality data into every customer interaction. This year’s theme, “Build The Experience AI Can’t,” will empower leaders to shift from doing more with AI to creating better experiences powered

Incode First to Achieve iBeta’s Highest Level of Independent Identity Security Testing on Both iOS and Android With 0% Error Rate2.3.2026 16:00:00 EET | Press release

Incode Technologies, Inc., the global leader in identity security and fraud prevention, today announced that iBeta PAD testing confirmed Incode’s face liveness technology achieves Level 3 Presentation Attack Detection (PAD) conformance under ISO/IEC 30107-3. "We are the first company to independently achieve iBeta Level 3 conformance on both iOS and Android – with zero errors and without adding friction to users," said Ricardo Amper, Founder & CEO at Incode. "That combination matters. It proves we can meet the highest bar for liveness assurance while keeping onboarding fast and easy, even in regulated and high-risk environments." Face liveness technology is used in digital onboarding and authentication to confirm a real, live person is present during a selfie capture – not a printed photo, video replay, mask, or other spoofing attempt. It enables organizations to defend remote identity verification flows against account takeovers, synthetic identity fraud, and impersonation scams. Inco

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye